VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

AIM2(-1)/HT001(-1)/TAF1B(-1) Frameshift Peptide Vaccine

Vaccine Information

Vaccine Name: AIM2(-1)/HT001(-1)/TAF1B(-1) Frameshift Peptide Vaccine
Target Pathogen: Cancer
Target Disease: Cancer
Vaccine Ontology ID: VO_0007215
Type: Other
Status: Clinical trial
Host Species for Licensed Use: Human
Host Species as Laboratory Animal Model: Human
AIM2 gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
TAF1B gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
ASTE1 gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
Preparation: To generate frameshift peptide specific TLC in vitro, peripheral blood mononuclear cells (PBMCs) from healthy donors were stimulated weekly with autologous peptide pulsed dendritic cells or PBMCs in bulk cultures for up to 5 weeks (Saeterdal et al., 2001).
Description: A cancer vaccine containing the three frame shift peptides (FSP) AIM2(-1), HT001(-1) and TAF1B(-1), with potential immunomodulating activity. Upon administration, the AIM2(-1)/HT001(-1)/TAF1B(-1) FSP vaccine may induce an immune response against microsatellite instability (MSI) colorectal cancer-associated antigens. Frame shift mutations of AIM2 (absent in melanoma 2, an interferon-inducible protein), HT001 (asteroid homolog 1 or ASTE1, with an unknown function) and TAF1B (TATA box-binding protein-associated RNA polymerase I B, a transcription factor) are seen in MSI-positive colorectal cancers and may be associated with malignant transformation, tumor progression and the presence of tumor-infiltrating lymphocytes. These FSPs all have one-base deletions. NCT01461148 (NCIT_C99129).

Host Response

References

NCIT_C99129: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C99129]

Saeterdal et al., 2001: Saeterdal I, Bjørheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Møller M, Lindblom A, Gaudernack G. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(23); 13255-13260. [PubMed: 11687624].